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Abstract
Introduction: The frequency and clinical significance of polymicrobial aetiology in community-acquired pneumonia
(CAP) patients admitted to the ICU have been poorly studied. The aim of the present study was to describe the
prevalence, clinical characteristics and outcomes of severe CAP of polymicrobial aetiology in patients admitted to the ICU.
Methods: The prospective observational study included 362 consecutive adult patients with CAP admitted to the
ICU within 24 hours of presentation; 196 (54%) patients had an established aetiology.
Results: Polymicrobial infection was present in 39 (11%) cases (20% of those with defined aetiology): 33 cases with
two pathogens, and six cases with three pathogens. The most frequently identified pathogens in polymicrobial
infections were Streptococcus pneumoniae (n = 28, 72%), respiratory viruses (n = 15, 39%) and Pseudomonas
aeruginosa (n = 8, 21%). Chronic respiratory disease and acute respiratory distress syndrome criteria were
independent predictors of polymicrobial aetiology. Inappropriate initial antimicrobial treatment was more frequent in
the polymicrobial aetiology group compared with the monomicrobial aetiology group (39% vs. 10%, P < 0.001), and
was an independent predictor of hospital mortality (adjusted odds ratio = 10.79, 95% confidence interval = 3.97 to
29.30; P < 0.001). The trend for higher hospital mortality of the polymicrobial aetiology group compared with the
monomicrobial aetiology group (n = 8, 21% versus n = 17, 11%), however, was not significantly different (P = 0.10).
Conclusions: Polymicrobial pneumonia occurs frequently in patients admitted to the ICU. This is a risk factor for
inappropriate initial antimicrobial treatment, which in turn independently predicts hospital mortality.
Introduction
Community-acquired pneumonia (CAP) remains a com-
mon and potentially life-threatening condition. Among
patients hospitalised by CAP, the rates of severe CAP
range from 6.6 to 16.7% [1].
The pathogens causing CAP may vary according to
geographic area and underlying risk factors. Appropriate
initial antimicrobial treatment has been repeatedly shown
to be crucial for the outcome in severe infections. The
knowledge of pathogen patterns causing CAP as the basis
for the selection of such treatment is therefore crucial.
Some studies have revealed that more than one causative
microorganism was present in a considerable amount of
cases. One of main problems for the studies on microbial
aetiology in CAP is that not all microbiological tests are
applied systematically for all patients. This limitation
could possibly imply that the real frequency of polymi-
crobial aetiologies in main series is often underestimated.
The reported rates for polymicrobial aetiology, how-
ever, differ considerably between 5.7 and 38.4% [2-7].
The clinical significance of polymicrobial aetiology in
CAP patients admitted to the ICU has not been specifi-
cally addressed. We therefore studied the prevalence,
clinical characteristics and outcomes of severe CAP of
polymicrobial aetiology in ICU patients.
Materials and methods
Ethics statement
The study was approved by the Ethics Committee of our
institution, but written informed consent was waived
due to the non-interventional design.
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Study population
The present cohort included 362 consecutive adult
patients with CAP admitted to the ICU within 24 hours
of admission to the emergency department in an 850-
bed tertiary care university hospital (Hospital Clinic of
Barcelona, Spain) between January 2003 and December
2010. The decision for admission to an ICU was made
by the attending physician in all cases.
Pneumonia was defined as a new pulmonary infiltrate
found on the hospital admission chest radiograph with
symptoms and signs of lower respiratory tract infection.
We excluded patients with immunosuppression (for
example, patients with neutropaenia after chemotherapy
or bone marrow transplantation, patients with drug-
induced immunosuppression as a result of solid-organ
transplantation or corticosteroid (> 10 mg/day) or cyto-
toxic therapy, and all HIV-infected patients) and health-
care-associated pneumonia patients.
Data collection and evaluation
The following parameters were recorded at admission: age,
sex, tobacco use, alcohol and drug consumption, co-mor-
bidities (chronic respiratory disease, including chronic
obstructive pulmonary disease, asthma and bronchiectasis
among others, diabetes mellitus, chronic cardiovascular
disease, neurological disease, chronic renal disease and
chronic liver disease), antibiotic treatment in the previous
30 days before hospital admission, treatment with corti-
costeroids, clinical symptoms and features (fever, cough,
pleuritic chest pain, dyspnoea, mental confusion and
aspiration), clinical signs (blood pressure, body tempera-
ture, respiratory rate and heart rate), arterial blood gas
measurements, chest radiograph findings (number of lobes
affected, pleural effusion and atelectasis), laboratory para-
meters (haemoglobin level, white blood cell count, platelet
count, serum creatinine level, C-reactive protein level and
other biochemical parameters), diagnostic procedures,
empiric antibiotic therapy, ventilatory support, pulmonary
complications (empyema, acute respiratory distress syn-
drome (ARDS) criteria, pleural effusion and surgical
pleural draining) and other clinical events (cardiac
arrhythmias, septic shock, and acute renal failure). The
duration of treatment, length of hospital stay and 30-day
in-hospital mortality were noted. We also calculated the
pneumonia severity index (PSI) at admission [8].
Microbiological evaluation and diagnostic criteria
Microbiological examination was performed in sputum,
urine, two samples of blood and nasopharyngeal swabs.
Pleural puncture, tracheobronchial aspirates and bronch-
oalveolar lavage (BAL) fluid, when available, were collected.
Conventional tests were used to evaluate the presence of
bacterial, parasitic and fungal agents, and of respiratory
viruses. Sputum, Bronchial aspirate sample (BAS) and BAL
specimens were stained using the Gram and Ziehl-Neelsen
methods for bacterial and mycobacteria detection, respec-
tively. In BAL samples, the following additional stains were
used: May-Grünwald Giemsa for fungal detection and cel-
lular differential count, and Gomori methenamine silver
for Pneumocystis jirovecii. Sputum and pleural fluid sam-
ples were qualitatively cultured for bacterial pathogens,
fungi and mycobacteria. Bronchial aspirate sample (BAS)
and BAL samples were homogenised and processed for
quantitative culture by serial dilutions for bacterial patho-
gens; undiluted cultures for Legionella spp., fungi and
mycobacteria were also carried out.
Nasopharyngeal swabs and BAL specimens were pro-
cessed for antigen detection by immunofluorescence assay
and for isolation of viruses in cell culture (influenza virus
A, influenza virus B, human parainfluenza viruses 1 to 3,
adenovirus and respiratory syncytial virus). In addition,
two independent multiplex-nested RT-PCR assays able to
detect from 1 to 10 copies of viral genomes were per-
formed for the diagnostics of respiratory viruses. One RT-
PCR assay detected influenza virus types A, B and C,
respiratory syncytial viruses A and B, and adenovirus.
Another RT-PCR assay studied parainfluenza viruses 1, 2,
3 and 4, coronaviruses 229E and OC43, rhinoviruses and
enteroviruses. All positive results were subsequently con-
firmed by a second independent assay.
Sputum and blood samples were obtained for bacterial
culture before the start of antibiotic therapy in the emer-
gency department. Nasopharyngeal swab for respiratory
virus detection and urine samples for Streptococcus pneu-
moniae and Legionella pneumophila antigen detection
were obtained within 24 hours after hospital admission.
Blood samples for serology of atypical pathogens and
respiratory virus were taken at admission and within the
third and sixth week thereafter.
Criteria for aetiological diagnosis
The aetiology was considered definite if one of the follow-
ing criteria was met: blood culture positive (in the absence
of an apparent extrapulmonary focus); positive bacterial
culture of pleural fluid or transthoracic needle aspiration
samples; elevated serum levels of IgM against Chlamydo-
phila pneumoniae (≥ 1:64), Coxiella burnetii (≥ 1:80) and
Mycoplasma pneumoniae (any positive titre); seroconver-
sion (that is, a fourfold increase in IgG titres) for C. pneu-
moniae and L. pneumophila > 1:128, C. burnetii > 1:80
and respiratory viruses (influenza viruses A and B, parain-
fluenza viruses 1 to 3, respiratory syncytial virus and ade-
novirus); positive urinary antigen for L. pneumophila
(Binax Now L. pneumophila urinary Antigen Test; Trinity
Biotech, Bray, Ireland); positive urinary antigen for S.
pneumoniae (Binax Now S. pneumoniae urinary Antigen
Test; Emergo Europe, The Hague, The Netherlands);
bacterial growth in cultures of tracheobronchial aspirates
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(≥ 105 cfu/ml), in a protected specimen brush (≥ 103 cfu/
ml) and in BAL (≥ 104 cfu/ml); and detection of antigens
by immunofluorescence assay plus virus isolation or detec-
tion by RT-PCR testing for respiratory virus (influenza
viruses A and B, parainfluenza viruses 1 to 3, respiratory
syncytial virus, rhinovirus and adenovirus).
The aetiology of pneumonia was classified as presump-
tive when a predominant microorganism was isolated
from a purulent sample (leukocytes > 25 per high-power
microscopic field and few epithelial cells < 10 per high-
power microscopic field) and the findings of Gram stain-
ing were compatible. For the purpose of the present study,
presumptive and definitive diagnostics were analysed
together.
Definitions
Polymicrobial pneumonia was defined as pneumonia due
to more than one pathogen. Severe CAP was defined
when at least one major criterion or three minor criteria
of the Infectious Disease Society of America/American
Thoracic Society (IDSA/ATS) guidelines were present [9].
Appropriateness of empiric antibiotic treatment was
defined when the isolated pathogens were susceptible in
vitro to one of the antimicrobials administrated according
to current European guidelines for microbiological sus-
ceptibility testing [10]. For Pseudomonas aeruginosa infec-
tion, adequate treatment needed a combination of two
active antibiotics against the isolated strain.
Statistical analysis
Categorical variables are described as frequencies and
percentages, while continuous variables are presented as
means and standard deviations, or as the median and
interquartile range for data not normally distributed
(Kolmogorov-Smirnov test). Categorical variables were
compared with the chi-square test or Fisher’s exact test
where appropriate. Continuous variables were compared
using the Student t test once normality was demonstrated;
otherwise, the nonparametric Mann-Whitney U test was
performed.
Univariate and multivariate logistic regression analyses
were performed to identify variables predictive of patients
with polymicrobial pneumonia (dependent variable). The
independent variables analysed were: age, gender, smok-
ing, alcohol consumption, previous antibiotic, influenza
vaccine, pneumococcal vaccine, inhaled corticosteroids,
systemic corticosteroids, chronic cardiovascular disease,
chronic renal failure, diabetes mellitus, chronic liver dis-
ease, neurological disease, chronic pulmonary disease,
fever, C-reactive protein level, white blood cell count, crea-
tinine, PSI, multilobar infiltration, ARDS criteria, shock
and mechanical ventilation. Univariate and multivariate
logistic regression analyses were performed to predict 30-
day mortality (dependent variable). The independent
variables were the previous plus the number of aetiologies
and adequacy of empirical treatment, with the exception
of ARDS, shock and mechanical ventilation. Variables that
showed a significant result univariately (P < 0.1) were
included in the multivariate logistic regression backward
stepwise model. The Hosmer-Lemeshow goodness-of-fit
test was performed to assess the overall fit of the model
[11]. All tests were two-tailed and significance was set at
5%. All analyses were performed with SPSS version 16.0
for Windows (SPSS Inc., Chicago, IL, USA).
Results
Patients’ characteristics
During the study period, 2,200 patients were hospitalised
with a diagnosis of CAP. Of these, 362 (16%) patients were
admitted to the ICU. The main characteristics of patients
and the outcome variables are shown in Table 1.
Among the 67 patients who had received antimicro-
bial treatment prior to hospital admission, the median
duration of treatment was 2.8 days. The types of anti-
biotics received were: 25 (8%) b-lactams, 20 (6%) fluoro-
quinolones, six (2%) macrolides and 16 (5%) unknown.
Aetiology
The specimens obtained included blood cultures from
330 (91%) patients, urine from 345 (95%) patients, acute
and follow-up sera from 150 (41%) patients, sputum
from 285 (79%) patients, bronchoscopically obtained
lower respiratory secretions from 84 (23%) patients,
pleural fluid in 62 (17%) patients, and nasopharyngeal
and oropharyngeal swabs from 180 (50%) patients.
The aetiology of CAP could be established in 196
(54%) ICU patients. The proportion of patients with
defined aetiology was higher in those with available
lower respiratory tract samples, which included sputum
and bronchoscopically obtained secretions (Table 2).
Patients with lower respiratory tract samples were more
severe, assessed by higher PSI risk classes, more fre-
quent septic shock, ARDS criteria and the need for
mechanical ventilation.
Monomicrobial infection was detected in 157 cases and
polymicrobial infection in 39 cases (11% of the overall
population and 20% of those with defined aetiology only),
with two pathogens isolated in 33 cases and three patho-
gens in six cases. As shown in Table 3, the most frequently
identified pathogens were S. pneumoniae, respiratory
viruses, P. aeruginosa, methicillin-resistant Staphylococcus
aureus (MRSA), Gram-negative enteric bacilli (GNEB) and
L. pneumophila.
Comparison of the monomicrobial and polymicrobial
aetiology
Patients with polymicrobial aetiology had previously
received antibiotics less frequently, had a higher
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proportion of chronic respiratory and neurological dis-
eases, less frequently presented fever at admission, had
higher rates of PSI risk class V, had severe CAP accord-
ing to the IDSA/ATS definition, and fulfilled ARDS cri-
teria. The length of hospital stay and hospital mortality
tended to be higher in these patients (Table 4).
As regards the aetiologic pathogens, the proportion of
respiratory viruses-particularly influenza A, MRSA, P.
aeruginosa, GNEB, Haemophilus influenzae and Morax-
ella catarrhalis - were more frequently isolated in
patients with polymicrobial pneumonia, without differ-
ences in the remaining pathogens (Table 3).
Empirical antibiotic therapy
Data on antibiotic treatment were available in 347
(96%) patients. The most frequent regimens were
fluoroquinolones plus b-lactam (n = 217, 63%), b-lac-
tam plus macrolide (n = 73, 21%), fluoroquinolone
monotherapy (n = 39, 11%) and b-lactam monotherapy
(n = 18, 5%). These regimens were similarly adminis-
tered in patients with monomicrobial or polymicrobial
aetiology.
The empirical antibiotic treatment was more fre-
quently inappropriate in patients from the polymicrobial
aetiology group (Table 4). When respiratory viruses
were not taken into account, the pathogens most fre-
quently associated with inadequate treatment were
MRSA in 10 cases, and S. pneumoniae, P. aeruginosa
and GNEB in nine cases each. None of our patients
received antiviral therapy.
Predictors of polymicrobial aetiology
Several variables were significantly associated with poly-
microbial pneumonia in the univariate logistic regres-
sion analyses (Table 5). Among these variables, chronic
respiratory disease and ARDS criteria at hospital admis-
sion were independent predictors of polymicrobial
aetiology in the multivariate analysis.
Predictors of hospital mortality
The univariate logistic regression analyses revealed sev-
eral variables significantly associated with hospital mor-
tality (Table 6). Although polymicrobial pneumonia
(that is, two or more pathogens identified) was asso-
ciated with increased mortality compared with the
absence of defined aetiology, the differences between
monomicrobial and polymicrobial aetiology were not
significant, as shown in Table 4.
Among these variables, age ≥ 65 years, neurological
disease, chronic liver disease and inappropriate antimi-
crobial treatment were independently associated with
increased hospital mortality in the multivariate analysis.
Table 1 Baseline characteristics of the whole population
(n = 362) at admission to the ICU
General characteristic Value
Demographics
Age (years) 63.4 ± 16.5
Sex (male) 232 (64%)
Current smoking 110 (31%)
Current alcohol abuse 77 (22%)
Previous antibiotic 67 (21%)
Influenza vaccine 140 (47%)
Pneumococcal vaccine 43 (14%)
Inhaled corticosteroid 89 (25%)
Systemic corticosteroid 23 (7%)
Co-morbidity
Chronic respiratory disease 134 (37%)
Chronic obstructive pulmonary disease 59 (16%)
Asthma 21 (6%)
Bronchiectasis 9 (3%)
Other 45 (12%)
Chronic cardiovascular disease 50 (14%)
Diabetes mellitus 70 (20%)
Neurological disease 68 (19%)
Chronic renal disease 23 (6%)
Chronic liver disease 23 (6%)
Clinical findings
Fever 281 (78%)
Diastolic blood pressure (mmHg) 70 (21)
Systolic blood pressure (mmHg) 120 (50)
Laboratory findings
Creatinine (mg/dl) 1.1 (0.7)
C-reactive protein level (mg/dl) 22.4 (20.8)
White blood cell count (109 cells/l) 13.4 (10.5)
Platelet count (109 platelets/l) 235.0 (127.0)
Oxygen saturation (%) 91.4 (8.5)
PaO2/FIO2 247.6 (99.5)
Pneumonia severity index
I to III 96 (27%)
IV 129 (37%)
V 126 (36%)
Bacteraemia 63 (18%)
Multilobar infiltration 159 (44%)
Pleural effusion 79 (22%)
Severe community-acquired pneumonia 201 (66%)
Mechanical ventilation 135 (44%)
Septic shock 72 (20%)
ARDS criteria 26 (7%)
Length of hospital stay (days) 11.0 (9.0)
Thirty-day mortality 37 (10%)
Data presented as mean ± standard deviation, n (%) or median (interquartile
range). ARDS, acute respiratory distress syndrome; PaO2/FIO2, arterial oxygen
tension to inspired oxygen fraction ratio. Other respiratory diseases include
sequelae of pulmonary tuberculosis, pulmonary hypertension and interstitial
lung disease.
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Discussion
Polymicrobial aetiology was found in 11% of all patients
with CAP admitted to the ICU, 20% considering those
with defined aetiology only. Although S. pneumoniae was
the most frequent pathogen in both groups, we found
MRSA, P. aeruginosa, GNEB, H. influenzae, M. catarrhalis
and respiratory viruses more frequently identified in poly-
microbial pneumonia than in monomicrobial pneumonia.
Chronic respiratory disease and ARDS criteria were inde-
pendent predictors of polymicrobial aetiology. Although
an independent predictor of hospital mortality such as
inappropriate treatment was more frequent in the polymi-
crobial aetiology group, the trend for higher hospital mor-
tality in patients from this group was not statistically
significant.
In general populations of hospitalised patients with
CAP, we have previously reported lower rates of polymi-
crobial pneumonia (5%) [3,12] than in this series of ICU
patients. Other studies on patients with CAP found
5.7% and 38.4% rates of polymicrobial aetiology in their
series [4,5]. These wide variations might be explained by
differences in the populations studied, epidemiological
settings, rate of antimicrobial pretreatment, microbiolo-
gical workup and definitions of aetiology. A typical lim-
itation of many studies dealing with microbial aetiology
in CAP is that not all microbiological tests are applied
systematically for all patients. This issue means that the
real frequency of polymicrobial aetiologies could possi-
bly be higher if a complete microbiological investigation
was performed in all cases. In view of these methodolo-
gical problems, it seems difficult to indicate precisely
the extent of the problem of polymicrobial aetiology.
Analysing the potential impact of polymicrobial aetiol-
ogy is therefore more important, particularly in the
most severely ill patients and in those at highest risk of
death.
S. pneumoniae was not only the most frequent patho-
gen but also by far the most frequent co-pathogen in
polymicrobial infections. This finding underlines the
importance of pneumococcal coverage in any initial
Table 2 Characteristics of patients with and without low respiratory tract samples
Characteristic With samples (n = 86) Without samples (n = 276) P value
Age (years) 64.4 ± 16.7 63.0 ± 16.4 0.39
Sex (male) 63 (73.3%) 169 (61.2%)
Age ≥ 65 years 47 (54.7) 149 (54) 0.91
Pneumonia severity index 0.049
I to III 13 (15.3%) 83 (31.2%)
IV 26 (30.6%) 103 (38.7%)
V 46(54.1%) 80 (30.1%)
Bacteraemia 18 (21.4%) 45 (17.4%) 0.40
Multilobar infiltration 46 (53.5%) 113 (40.9%) 0.041
Severe community-acquired pneumonia 66 (83.5%) 135 (59.2%) 0.001
Mechanical ventilation 60(81.1%) 75 (32.1%) 0.001
ARDS criteria 17 (19.8%) 9 (33.3%) 0.001
Septic shock 30 (34.9%) 42 (15.3%) 0.001
Length of hospital stay (days) 24.7 (20.7) 12.8 (10.5) < 0.001
Thirty-day mortality 19 (22.1%) 18 (6.5%) 0.001
Aetiology 60(70%) 136 (49%) 0.002
Streptococcus pneumoniae 29 (48.3%) 93 (68.4%)
Staphylococcus aureus 3 (5%) 4 (2.9%)
MRSA 8 (13.3%) 6 (4.4%)
Legionella pneumophila 1 (1.7%) 10 (7.4%)
Chlamydophila pneumophila 1 (1.7%) 5 (3.7%)
Haemophilus influenzae 5 (8.3%) 3 (2.2%)
Virus 10 (16.7%) 21(15.4%)
Coxiella burnetii 1 (1.7%) 2 (1.5%)
Streptococcus viridans 1 (1.7%) 0
Mycoplasma pneumoniae 4 (6.7%) 2 (1.5%)
Pseudomonas aeruginosa 7 (11.7%) 7 (5.1%)
Gram-negative enteric bacilli 5 (8.3%) 5 (3.7%)
Data presented as mean ± standard deviation, n (%) or median (interquartile range). ARDS, acute respiratory distress syndrome; MRSA, methicillin-resistant
Staphylococcus aureus.
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antimicrobial treatment regimen. The most frequent
polymicrobial pattern was S. pneumoniae and viral infec-
tion, particularly influenza virus. Pneumococci have been
identified as the most frequent bacterial superinfection in
both seasonal [13] and novel H1N1 [14,15] influenza
virus-associated pneumonia.
Interestingly, whereas S. pneumoniae was by far the
most frequent single pathogen, the rate of this pathogen
was similar among patients with monomicrobial aetiology
and those with polymicrobial aetiology. Among the patho-
gens more frequently identified in polymicrobial pneumo-
nia, respiratory viruses were the most frequent. We did
not find that polymicrobial aetiology was associated with
higher mortality. Viruses were the most frequent microor-
ganisms associated with polymicrobial aetiology. Except
for influenza A H1N1, viruses are not a cause of excess
mortality-as recently pointed out by two recent studies
[13,16]. The role of viruses in the aetiology of pneumonia
is unclear, since they may be regarded either as primary
infection or, with bacteria, as representing superinfection
[17]. None of our patients received antiviral treatment.
We feel that at least during the influenza season, however,
patients could benefit from antiviral treatment.
The role of MRSA in CAP is limited in Europe, even if
patients meeting criteria for healthcare-associated pneu-
monia remain included [18]. Although for our series we
excluded patients with healthcare-associated pneumonia,
the frequent association of this pathogen with severe
underlying illness [19] may explain the higher rate of this
pathogen in the polymicrobial aetiology group, since
these patients were more severe at admission than those
with monomicrobial aetiology. The exact role of MRSA
in polymicrobial CAP is difficult to assess, however,
because even a high bacterial load of MRSA may still
represent colonisation rather than infection [20]. The
higher rate of P. aeruginosa and GNEB in polymicrobial
Table 3 Distribution of the causative microorganisms identified in 196 patients with community-acquired pneumonia
Microorganism Monomicrobial aetiology
(n = 157)
Polymicrobial aetiology
(n = 39)
P
value
Two pathogens
(n = 33)
Three pathogens
(n = 6)
Streptococcus pneumoniae 94 (60) 28 (72) 0.17 23 (70) 5 (83)
Streptococcus pyogenes 1 (1) 1 (3) 0.36 1 (3) -
Streptococcus viridansa - 1 (3) 0.20 1 (3) -
Staphylococcus aureus
(MSSA)
4 (3) 3 (8) 0.12 2 (6) 1 (17)
Staphylococcus aureus
(MRSA)
5 (3) 9 (23) <
0.001
5 (15) 4 (67)
Haemophilus influenzae 4 (3) 4 (10) 0.029 3 (9) 1 (17)
Moraxella catarrhalis 1 (1) 2 (5) 0.041 1 (3) 1 (17)
Gram-negative enteric
bacillib
6 (4) 7 (18) 0.002 5 (15) 2 (33)
Pseudomonas aeruginosa 6 (4) 8 (21) <
0.001
6 (18) 2 (33)
Respiratory viruses 16 (10) 15 (39) <
0.001
14 (42) 1 (17)
Rhinovirus 2 (1) 2 (5) 0.13 2 (6) -
Adenovirus 1 (1) 1 (3) 0.36 1 (3) -
Respiratory syncitial
virus
2 (1) 2 (5) 0.13 2 (6) -
Influenza virus A 10 (6) 9 (23) 0.002 8 (24) 1 (17)
Influenza virus B 1 (1) 1 (3) 0.36 1 (3) -
Legionella
pneumophila
10 (6) 1 (3) 0.36 1 (3) -
Atypical 10 (6) 5 (13) 0.18 4 (12) 1 (17)
Mycoplasma
pneumoniae
4 (3) 2 (5) 0.40 2 (6) -
Chlamydophila
pneumoniae
4 (3) 2 (5) 0.40 1 (3) 1 (17)
Coxiella burnetii 2 (1) 1 (3) 0.49 1 (3) -
Data presented as n (%). Percentages refer to the total number of patients of each group (monomicrobial vs. polymicrobial). The most frequent combinations in
cases with two pathogens were S. pneumoniae with respiratory viruses (11 cases), P. aeruginosa (three cases), and H. influenzae, Gram-negative enteric bacilli and
atypicals in two cases each. The most frequent combination in cases with three pathogens was S. pneumoniae, Gram-negative enteric bacilli and methicillin-
resistant Staphylococcus aureus (MRSA) in two cases. P value refers to a statistical comparison of cases with monomicrobial aetiology and polymicrobial aetiology.
MSSA, methicillin-susceptible Staphylococcus aureus. aS. viridans isolated from a pleural fluid specimen. bIncluding Escherichia coli, Klebsiella pneumoniae, Serratia
marcescens.
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pneumonia may also be related to the higher rate of
chronic respiratory diseases in this group, since identifi-
cation of these pathogens occurs more frequently in
those with chronic lung disease [21]. As for MRSA, the
identification of P. aeruginosa does not necessarily mean
this is the causative pathogen of acute exacerbation in all
chronic obstructive pulmonary disease patients colonised
by the pathogen [22], and similarly MRSA eventually
may represent colonisation rather than infection in
patients with pneumonia.
We identified chronic respiratory disease and ARDS
criteria as independent predictors of polymicrobial
aetiology. In chronic obstructive pulmonary disease, this
finding can be explained by the previous colonisation of
Table 4 Characteristics of patients with defined aetiology, comparing monomicrobial and polymicrobial pneumonia
Variable Monomicrobial CAP (n = 157) Polymicrobial CAP (n = 39) P value
Demographics
Age (years) 61.6 ± 17.7 63.5 ± 14.1 0.48
Sex (male) 106 (68%) 23 (59%) 0.31
Current smoking 46 (30%) 13 (35%) 0.53
Current alcohol abuse 32 (21%) 12 (33%) 0.11
Previous antibiotic 30 (22%) 2 (7%) 0.051
Influenza vaccine 50 (39%) 9 (35%) 0.65
Pneumococcal vaccine 20 (16%) 2 (8%) 0.29
Inhaled corticosteroid 29 (19%) 11 (31%) 0.10
Systemic corticosteroid 11 (7%) 4 (12%) 0.34
Co-morbidity
Chronic respiratory disease 50 (32%) 21 (54%) 0.011
Chronic cardiovascular disease 21 (14%) 1 (3%) 0.068
Diabetes mellitus 26 (17%) 4 (11%) 0.40
Neurological disease 19 (12%) 9 (25%) 0.052
Chronic renal disease 10 (7%) 2 (6%) 0.84
Chronic liver disease 9 (6%) 5 (13%) 0.11
Clinical findings
Fever 132 (84%) 27 (69%) 0.034
Diastolic blood pressure (mmHg) 68.0 (20.0) 70.0 (22.0) 0.38
Systolic blood pressure (mmHg) 120.0 (48.0) 121.0 (63.0) 0.23
Laboratory findings
Creatinine (mg/dl) 1.2 (0.8) 1.3 (0.7) 0.57
C-reactive protein level (mg/dl) 25.2 (20.3) 26.5 (11.6) 0.24
White blood cell count (109 cells/l) 13.1 (12.1) 9.5 (13.4) 0.019
Oxygen saturation (%) 93 (7.9) 92.0 (7.3) 0.78
PaO2/FIO2 254.3 (84.6) 247.6 (104.8) 0.38
Inappropriate empirical treatment 15 (10%) 15 (39%) < 0.001
Pneumonia severity index
I to III 44 (29%) 10 (28%) 0.89
IV 60 (40%) 8 (22%) 0.053
V 48 (32%) 18 (50%) 0.037
Severe CAP 94 (68%) 31 (86%) 0.029
Bacteraemia 47 (32%) 14 (39%) 0.45
Multilobar infiltration 74 (47%) 27 (69%) 0.013
Pleural effusion 36 (23%) 9 (24%) 0.94
Mechanical ventilation 60 (43%) 21 (62%) 0.047
ARDS criteria 6 (4%) 12 (31%) < 0.001
Septic shock 38 (24%) 14 (36%) 0.14
Length of hospital stay (days) 12.0 (11.0) 15.0 (10.0) 0.082
Thirty-day mortality 17 (11%) 8 (21%) 0.10
Data presented as mean ± standard deviation, n (%) or median (interquartile range). ARDS, acute respiratory distress syndrome; CAP, community-acquired
pneumonia; PaO2/FIO2, arterial oxygen tension to inspired oxygen fraction ratio. Other respiratory diseases include sequelae of pulmonary tuberculosis,
pulmonary hypertension and interstitial lung disease.
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different bacteria these patients may have in their lower
airways. On the contrary, ARDS may be the conse-
quence of a mixed infection with higher pulmonary
insult. In both chronic obstructive pulmonary disease
and ARDS with severe CAP, our recommendation is to
give a broad empirical antibiotic treatment from the
beginning of therapy because mixed infections are more
frequent [23,24].
A relevant issue in polymicrobial aetiology of severe
CAP refers to its potential prognostic implications. We
found a strong association between polymicrobial aetiol-
ogy and initial inappropriate antimicrobial treatment,
which in turn was an independent predictor of increased
hospital mortality. Inappropriate empiric treatment has
already been associated with poor outcome in patients
with severe infections [25,26]. Although crude mortality
was near double in patients with polymicrobial aetiol-
ogy, this difference did not reach statistical significance-
probably due to the insufficient number of patients
included. These results indicate that the impact of initial
inappropriate antimicrobial treatment is crucial for
survival, and that polymicrobial aetiology is an impor-
tant determinant for such inappropriateness.
To the best of our knowledge, this is the first study
addressing the issue of multiple aetiologies of CAP in a
large population of ICU patients. We decided to include
all patients admitted to the ICU regardless of whether
they met IDSA/ATS severity criteria. We think that clin-
ical decisions for ICU admission may be valid, while the
IDSA/ATS severity criteria have proven to be overly
sensitive [1,12].
Several limitations have to be addressed. First, the com-
plete diagnostic workup and microbiological sampling
could not be applied in every patient. Second, the true
incidence of polymicrobial aetiology may be underesti-
mated since 21% patients had received prior antimicrobial
treatment. Finally, viral infections may have been missed
since paired serology is frequently not available in nonsur-
vivors. We did not include molecular techniques such as
PCR for bacterial detection. We believe that the systematic
use of qualitative and quantitative PCR for the diagnosis of
respiratory infections may increase substantially the
Table 5 Univariate and multivariate logistic regression analyses of predictors of polymicrobial pneumonia
Variable Univariate analysis Multivariate analysisa
Odds ratio 95% CI P value Adjusted odds ratio 95% CI P value
Previous antibiotic 0.25 0.06 to 1.11 0.068 - - -
Neurological disease 2.39 0.98 to 5.83 0.057
Chronic respiratory disease 2.50 1.22 to 5.10 0.012 2.86 1.31 to 6.25 0.008
Fever 0.43 0.19 to 0.95 0.037 - - -
WBC (+10 × 109 cells/l)b 0.61 0.38 to 0.98 0.041 - - -
Multilobar infiltration 2.52 1.19 to 5.34 0.015 - - -
Mechanical ventilation 2.15 1.00 to 4.64 0.050 - - -
ARDS criteria 11.11 3.84 to 32.14 < 0.001 12.31 4.08 to 37.12 < 0.001
ARDS, acute respiratory distress syndrome; CI, confidence interval; WBC, white blood cells. aHosmer-Lemeshow goodness-of-fit test, P = 0.55. bIncrease by 10 ×
109 cells/l.
Table 6 Univariate and multivariate logistic regression analysis of predictors of mortality
Variable Univariate analysis Multivariate analysisa
Odds ratio 95% CI P value Adjusted odds ratio 95% CI P value
Age ≥ 65 years 2.49 1.17 to 5.32 0.018 3.06 1.27 to 7.41 0.013
Diabetes mellitus 2.25 1.06 to 4.76 0.034 - - -
Neurological disease 2.04 0.95 to 4.38 0.068 2.63 1.07 to 6.48 0.036
Chronic liver disease 5.63 2.20 to 14.39 < 0.001 8.99 2.91 to 27.77 < 0.001
Fever 0.49 0.24 to 1.01 0.053 - - -
Pneumonia severity index IV to V 4.77 1.43 to 15.91 0.011 - - -
Multilobar infiltration 2.28 1.13 to 4.60 0.021 - - -
Number of pathogens identifiedb 0.055 - - -
None 1 - -
Monomicrobial 1.56 0.72 to 3.38 0.26 - - -
Polymicrobial 3.31 1.25 to 8.77 0.016 - - -
Inappropriate empiric treatment 11.23 4.44 to 28.38 < 0.001 10.79 3.97 to 29.30 < 0.001
aHosmer-Lemeshow goodness-of-fit test, P = 0.81. bThe P value corresponds to differences between the three groups (none, one or more than one pathogen).
The odds ratio and 95% confidence interval (CI) of monomicrobial and polymicrobial pneumonia are related to cases with no pathogen identified.
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number of identified bacterial pathogens [7,27]. Moreover,
these new techniques could play a crucial role in the
determination of the clinical impact of polymicrobial
aetiology in CAP. Unfortunately, the use of molecular
techniques is not yet part of the routine diagnostic workup
in CAP.
Conclusions
Polymicrobial aetiology is a frequent finding in patients
with CAP admitted to the ICU. Our data support the
potential implication of polymicrobial pneumonia in the
outcome of patients related to an increased risk of inap-
propriate antimicrobial treatment, and suggests the
importance of an extensive microbiological testing in
very severe CAP patients since the CAP may be caused
by more than one aetiology.
The most important clinical implication of the identi-
fied predictors of polymicrobial aetiology is to empha-
sise the use of broad-spectrum antimicrobial treatment
in these groups of patients.
Key messages
• Polymicrobial aetiology is frequent among patients
with CAP admitted to the ICU and may result in
inappropriate empiric antimicrobial treatment.
• Polymicrobial aetiology of CAP should be sus-
pected in the presence of chronic respiratory disease
or criteria for ARDS.
• If antimicrobial treatment is appropriate, polymi-
crobial aetiology does not result in increased hospital
mortality from severe CAP.
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